EQS-Adhoc: Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised

Ad hoc NOTICE

Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)

Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised

Dreieich, 28 April 2023. The Supervisory Board approved the signing and execution of several agreements by the Board of Management to further strengthen the cooperation between Grifols S.A. and Biotest AG in research & development, manufacturing, operations as well as sales and distribution.

A Technology Transfer Agreement and a License Agreement will ensure that the new product developments of Biotest will be manufactured and commercialized worldwide by also using the organization and facilities of Grifols. A payment for the transferred technology and later royalty payments depending on net sales of the licensed products were agreed as consideration. The payment for the technology will have a positive effect on the EBIT of Biotest in a triple-digit million range.

The Board of Management raises the EBIT guidance for 2023 given in March 2023 from € -15 to -20 million to a level that can possibly exceed € 100 million. A more specific statement is subject to revenue recognition considerations regarding final project milestones.

Biotest Aktiengesellschaft
The Board of Management
 

Biotest AG

Landsteinerstr. 5

D-63303 Dreieich

www.biotest.com

Disclaimer

This document contains forward-looking statements on the overall economic development and the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on the company's current plans, estimates, forecasts and expectations and are therefore subject to risks and uncertainties that could cause actual developments to differ materially from those anticipated. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and does not assume any obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest is part of the Grifols Group, Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Buttkereit

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

1620119  28-Apr-2023 CET/CEST